A microfluidic cell culture platform for personalizing pancreatic cancer therapies
用于个性化胰腺癌治疗的微流控细胞培养平台
基本信息
- 批准号:9882916
- 负责人:
- 金额:$ 29.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAddressAutomationBiosensing TechniquesBiosensorCA-19-9 AntigenCancer BiologyCancer EtiologyCell Culture TechniquesCellsCessation of lifeCharacteristicsChemotherapy-Oncologic ProcedureClinicClinicalCollagenConsensusDetectionDevelopmentDevicesDiagnosisDiagnostic radiologic examinationDigestionDimensionsDiseaseDrug resistanceE-CadherinEnrollmentEpithelialEpitheliumExtracellular MatrixFibroblastsFutureGelGenerationsGoalsGuidelinesHeterogeneityImageImmunoassayIncidenceLife ExpectancyMaintenanceMalignant NeoplasmsMalignant neoplasm of pancreasMeasurementMicrofluidic MicrochipsMicrofluidicsMutationNewly DiagnosedOncologyPaclitaxelPatientsPharmaceutical PreparationsPhenotypeProcessReagentRegimenResistanceRetrievalSelection for TreatmentsSonalSurvival RateSystemTNF geneTestingTimeTimeLineTreatment ProtocolsUnited StatesWorkXenograft procedurecancer cellcancer therapycellular engineeringchemotherapycytotoxicitydesignexperienceexperimental studygemcitabineimprovedindividual patientmatrigelmouse modelnovelpancreatic cancer cellspatient responsepersonalized chemotherapypersonalized medicineresponsetooltreatment responsetumorvalidation studies
项目摘要
Pancreatic cancer is expected to become the second leading cause of cancer death in the United States by
2030. Because this cancer is asymptomatic at the early stage, patients are diagnosed at the advanced stage
and have a 5 year survival rate of less than 5%. The benefit from `one-size-fits-all' approach to treating pan-
creatic cancer has reached a plateau, partly due to high incidence of chemotherapy resistance and
heterogeneity associated with this disease. Novel tools are needed to address these problems and to improve
the survival of patients afflicted by this deadly cancer.
About 40% of newly diagnosed patients have a metastatic form of pancreatic cancer. Typical survival time for
such patients is between 8 and 10 months; therefore, it is extremely important to initiate the most efficacious
therapy as soon as possible. All patients with metastatic pancreatic cancer receive a chemotherapy regimen.
A patient is enrolled into either a FOLFIRINOX or gemcitabine/nab-paclitaxel regimen. At the present time, the
decision of which chemotherapy regimen to use is driven by general consensus guidelines and not by the tu-
mor characteristics of an individual patient. Treatment response is typically evaluated by radiographical
imaging performed every two months, and only 30% of patients respond to the chosen chemotherapy regimen.
Precious time is lost as a result. Such trial-and-error approach to therapy selection for treating an aggressive
cancer is simply unacceptable. Our team proposes to accelerate and personalize therapy selection process by
developing a microfluidic platform for cultivating cancer cells and evaluating drug responsiveness for patients
with metastatic pancreatic cancer. Our long term goal is to establish clinical utility of microfluidic cancer cul-
tures for personalizing chemotherapy. Upon successful completion of the current project, the microfluidic
culture platform will be incorporated into future clinical validation studies.
胰腺癌预计将成为美国癌症死亡的第二大原因
2030年,由于这种癌症早期无症状,患者确诊时已是晚期
且5年生存率低于5%。 “一刀切”治疗方法的好处
胰腺癌已达到一个平台期,部分原因是化疗耐药性的高发生率和
与这种疾病相关的异质性。需要新的工具来解决这些问题并改进
患有这种致命癌症的患者的生存。
大约 40% 的新诊断患者患有转移性胰腺癌。典型的生存时间
此类患者年龄在8至10个月之间;因此,采取最有效的措施极为重要
尽快治疗。所有转移性胰腺癌患者均接受化疗方案。
患者参加 FOLFIRINOX 或吉西他滨/白蛋白结合型紫杉醇治疗方案。目前,
使用哪种化疗方案的决定是由普遍共识指南驱动的,而不是由实际情况决定的。
更多个体患者的特征。治疗反应通常通过放射学评估
每两个月进行一次影像学检查,只有 30% 的患者对所选化疗方案有反应。
结果就浪费了宝贵的时间。这种用于治疗侵袭性疾病的治疗选择的试错方法
癌症是根本不可接受的。我们的团队建议通过以下方式加速和个性化治疗选择过程
开发用于培养癌细胞和评估患者药物反应的微流体平台
患有转移性胰腺癌。我们的长期目标是建立微流控癌症培养的临床应用
个性化化疗的理论。当前项目成功完成后,微流控
培养平台将纳入未来的临床验证研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Revzin其他文献
Alexander Revzin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Revzin', 18)}}的其他基金
Mass spectrometry for highly sensitive and sample-sparing analysis of extracellular vesicles in liver diseases
用于肝脏疾病细胞外囊泡高灵敏度和样品节省分析的质谱法
- 批准号:
10736006 - 财政年份:2023
- 资助金额:
$ 29.1万 - 项目类别:
A microfluidic cell culture platform for personalizing pancreatic cancer therapies
用于个性化胰腺癌治疗的微流控细胞培养平台
- 批准号:
10155447 - 财政年份:2020
- 资助金额:
$ 29.1万 - 项目类别:
Context rich mass spectrometry of molecular localization and cellular interactions
分子定位和细胞相互作用的上下文丰富质谱分析
- 批准号:
9751908 - 财政年份:2017
- 资助金额:
$ 29.1万 - 项目类别:
Microsystems for Shaping Stem Cell Fate Selections
用于塑造干细胞命运选择的微系统
- 批准号:
9412328 - 财政年份:2016
- 资助金额:
$ 29.1万 - 项目类别:
Microsystems for Shaping Stem Cell Fate Selections
用于塑造干细胞命运选择的微系统
- 批准号:
9889953 - 财政年份:2016
- 资助金额:
$ 29.1万 - 项目类别:
Microsystems for Shaping Stem Cell Fate Selections
用于塑造干细胞命运选择的微系统
- 批准号:
9215666 - 财政年份:2016
- 资助金额:
$ 29.1万 - 项目类别:
Novel heterotypic cell cultures for liver toxicology studies
用于肝毒理学研究的新型异型细胞培养物
- 批准号:
8323544 - 财政年份:2011
- 资助金额:
$ 29.1万 - 项目类别:
Novel heterotypic cell cultures for liver toxicology studies
用于肝毒理学研究的新型异型细胞培养物
- 批准号:
8054693 - 财政年份:2011
- 资助金额:
$ 29.1万 - 项目类别:
Designing a Microenvironment Niche for Liver-Specific Differentiation of hESCs
设计 hESC 肝脏特异性分化的微环境
- 批准号:
8247791 - 财政年份:2010
- 资助金额:
$ 29.1万 - 项目类别:
Designing a Microenvironment Niche for Liver-Specific Differentiation of hESCs
设计 hESC 肝脏特异性分化的微环境
- 批准号:
8448619 - 财政年份:2010
- 资助金额:
$ 29.1万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
3D 力传感鞋垫,用于可穿戴、人工智能支持的高保真步态监控
- 批准号:
10688715 - 财政年份:2023
- 资助金额:
$ 29.1万 - 项目类别:
Open-source Software Development Supplement for 3D quantitative analysisof mouse models of structural birth defects through computational anatomy
通过计算解剖学对结构性出生缺陷小鼠模型进行 3D 定量分析的开源软件开发补充
- 批准号:
10839199 - 财政年份:2023
- 资助金额:
$ 29.1万 - 项目类别:
3D Bioprinting of a Bioelectric Cell Bridge for Re-engineering Cardiac Conduction
用于重新设计心脏传导的生物电细胞桥的 3D 生物打印
- 批准号:
10753836 - 财政年份:2023
- 资助金额:
$ 29.1万 - 项目类别:
Automated Planning and Robotic Delivery of Needle Biopsies under CT Image Guidance
CT 图像引导下穿刺活检的自动规划和机器人传送
- 批准号:
10619755 - 财政年份:2023
- 资助金额:
$ 29.1万 - 项目类别: